Siberian Journal of Oncology,
Journal Year:
2024,
Volume and Issue:
23(5), P. 47 - 58
Published: Nov. 6, 2024
Assessment
of
tumor
infltrating
lymphocytes
(TiLs)
has
been
recognized
as
an
additional
tool
for
predicting
survival
in
triple
negative
(TN)
and
HER2/neu
positive
(HER2+)
subtypes
breast
cancer
(BC).
Recently,
BC,
including
the
above-mentioned
characterized
by
low/undefined
expression
HER2/neu,
isolated
into
a
separate
group,
designated
HER2-low
BC.
The
relationship
between
clinical
morphological
parameters
infiltration
immunocompetent
cells,
associated
macrophages
(TAM),
not
studied
to
date.
purpose
study
was
identify
significant
relationships
level
subpopulations
cells
(Tils
+
TAM)
Material
Methods
.
examined
surgical
specimens
33
patients
with
Visual
counting
TILs
assessment
(IHC)
T-helpers,
T-killers,
M1
M2
were
carried
out
intratumor
sites
invasive
edge
primary
tumor.
Results
mastectomy
showed
that
Tils
(Me=5
[5;
10]
%)
observed
all
patients.
found
be
highest
both
margin
(CD163inv:
Me=20
[10;
40]
%;
CD163c:
Me=15
[7;
30]
%,
respectively).
In
high
(≥20
levels
margin,
there
also
other
perineural
invasion
detected
significantly
more
often
(р=0.019).
Conclusion
A
is
combined
detection
cancer,
which
one
predictors
risk
progression.
combination
parameters,
may
become
another
factor
disease
prognosis.
Biochemical Pharmacology,
Journal Year:
2024,
Volume and Issue:
223, P. 116178 - 116178
Published: March 30, 2024
Despite
the
significant
improvements
made
in
breast
cancer
therapy
during
last
decades,
this
disease
still
has
increasing
incidence
and
mortality
rates.
Different
targets
involved
general
processes,
like
cell
proliferation
survival,
have
become
alternative
therapeutic
options
for
disease,
with
some
of
them
already
used
clinic,
CDK4/6
inhibitors
luminal
A
tumors
treatment.
Nevertheless,
there
is
a
demand
novel
strategies
focused
not
only
on
tumor
cells,
but
also
their
microenvironment.
Tumor
microenvironment
(TME)
very
complex
dynamic
system
that,
more
than
surrounding
supporting
actively
participates
development
progression.
During
it
clear
that
cellular
acellular
components
TME
differ
between
various
subtypes
shape
differences
regarding
severity
prognosis.
The
pivotal
role
controlling
growth
influencing
responses
to
represents
potential
source
strategies.
In
review,
we
present
description
multiple
different
subtypes,
as
well
influence
may
exert
response
distinct
therapies,
which
cases
explain
failure
by
occurrence
relapses
resistance.
Furthermore,
ongoing
studies
use
developing
treatments
are
described.
Future Oncology,
Journal Year:
2024,
Volume and Issue:
20(18), P. 1237 - 1250
Published: April 9, 2024
Trastuzumab
deruxtecan
(T-DXd)
is
approved
for
the
treatment
of
human
epidermal
growth
factor
receptor
2
(HER2)-low
metastatic
breast
cancer
(mBC).
Results
on
T-DXd
in
HER2-low
mBC
have
so
far
been
limited
to
clinical
trials.
DESTINY-Breast
Respond
Europe
(NCT05945732)
a
multi-center,
multi-country,
observational,
prospective,
non-interventional
study
planning
enroll
1350
patients
from
216
sites
receiving
or
conventional
chemotherapy
as
their
routine
care
advanced
stage
12
European
countries.
This
will
provide
real-world
insight
into
with
data
effectiveness,
safety
and
tolerability,
patient-reported
outcomes,
patterns,
geriatric
health
status
HER2
testing.
be
beneficial
improving
guidance
maximize
patient
benefit.
Radiology and Oncology,
Journal Year:
2024,
Volume and Issue:
58(2), P. 258 - 267
Published: June 1, 2024
Abstract
Background
Recent
evidence
brought
by
novel
anti-human
epidermal
growth
factor
receptor
2
(HER2)
antibody-drug
conjugates
is
leading
to
significant
changes
in
HER2-negative
breast
cancer
(BC)
best
practices.
A
new
targetable
category
termed
‘HER2-low’
has
been
identified
tumors
previously
classified
as
‘HER2-negative’.
Daily
practice
pathology
and
medical
oncology
expected
align
current
recommendations,
but
patient
access
anticancer
drugs
across
geographies
might
be
impeded
due
local
challenges.
Materials
methods
An
expert
meeting
involving
ten
regional
opinion
leaders
experienced
BC
management
four
Central
Eastern
Europe
(CEE)
countries
(Bulgaria,
Croatia,
Serbia,
Slovenia)
was
held.
Herein
we
summarized
the
situation
of
HER2-low
metastatic
(mBC),
challenges,
action
plans
prevent
delays
testing
treatment
based
on
opinion.
Results
Gaps
differences
at
multiple
levels
were
countries.
These
included
variability
epidemiology
data,
certification
laboratories
quality
control,
reimbursement
conditions
for
mBC.
While
clinical
decisions
aligned
international
guidelines
use,
optimal
innovative
restricted
or
limitative
conditions.
Conclusions
Preventing
mBC
diagnosis
treatments
crucial
optimize
outcomes.
Multidisciplinary
joint
efforts
pro-active
discussions
between
clinicians
decision
makers
are
needed
improve
care
patients
CEE
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(13), P. 7381 - 7381
Published: July 5, 2024
Oestrogen
receptor
(ER)-positive
breast
cancer
(BC)
is
generally
well
responsive
to
endocrine
therapy.
Neoadjuvant
therapy
(NAET)
increasingly
being
used
for
downstaging
ER-positive
tumours.
This
study
aims
analyse
the
effect
of
NAET
on
a
well-characterised
cohort
BC
with
particular
emphasis
expression.
retrospective
United
Kingdom
(UK)
multicentre
391
patients
who
received
between
October
2012
and
2020.
Detailed
analyses
paired
pre-
post-NAET
morphological
changes
hormone
(HR)
human
epidermal
growth
factor
2
(HER2)
expression
were
performed.
The
median
duration
was
86
days,
survival
overall
rates
380
days
93.4%,
respectively.
A
total
90.3%
cases
achieved
pathological
partial
response,
significantly
higher
rate
response
in
HER2-low
cancers.
Following
NAET,
displayed
some
involving
tumour
stroma
including
central
scarring
an
increase
infiltrating
lymphocytes
(TILs)
cell
morphology.
Significant
associated
observed
grade
(30.6%
cases),
downgrading
identified
19.3%
tumours
(p
<
0.001).
conversion
ER
status
from
positive
low
or
negative
insignificant.
progesterone
(PR)
HER2
31.3%
38.1%
cases,
respectively
decreased
63%
37%
following
samples.
biomarker
PR
occurred
NAET.
findings
support
testing
pre-treatment
core
biopsies
post-treatment
residual
carcinoma.
Current Medicinal Chemistry,
Journal Year:
2024,
Volume and Issue:
31(18), P. 2486 - 2506
Published: Jan. 12, 2024
Abstract:
Breast
cancer
(BC)
currently
represents
one
of
the
most
prevalent
cancers
among
women
worldwide
and
leading
cause
death
women,
also
negatively
affecting
quality
life
(QoL)
in
patients.
Over
past
two
decades,
BC
research
has
led
to
extraordinary
advances
our
understanding
disease,
resulting
more
effective
treatments.
However,
its
occurrence
is
still
increasing.
Several
new
treatments
are
now
under
development
worldwide,
but
they
not
devoid
wellknown
side
effects,
a
great
number
patients
develop
endocrine
resistance.
Nevertheless,
design
synthesis
suitable
strategies
drugs
treat
breast
cancers,
overcome
resistance
obtain
better
therapeutic
outcomes
needed.
In
this
review,
we
summarize
therapies
clinical
studies
ongoing
Italy
for
treatment
BCs,
mainly
HER2+
MBC,
HER2-low
TNBC,
focusing
on
recent
ones,
consideration
diverse
facets,
including
some
aspects
related
QoL.
Finally,
usefulness
physical
activity
will
be
cited.
